Market access implications of the new Irish 2022-2025 IPHA / HSE framework agreement

Market access implications of the new Irish 2022-2025 IPHA / HSE framework agreement

0.00 ex. VAT

Market access implications of the new Irish IPHA / HSE framework agreement

As you will be aware a new framework agreement on the supply and pricing of medicines for Ireland was published on December 6th, 2021. This new agreement sets out the reimbursement terms and conditions for all new and existing medicines for the period October 1st, 2021 – 30th September 2025.

At the webinar, I along with my colleague Cillian Copeland, will shine the spotlight on what’s new in this agreement and tease out the key implications for pharmaceutical companies who are making pricing and reimbursement applications to the Irish authorities.

We are delighted to announce that Jim McGrath, Director of Commercial Policy at the Irish Pharmaceutical Healthcare Association (IPHA) will join the webinar as our guest presenter. Jim will speak about IPHA’s role in negotiating a new agreement with the other key stakeholders, the Department of Health, the Department of Public Expenditure and Reform and the Health Service Executive.

This free of charge event is for pharmaceutical company employees only. Places are limited so if you wish to attend, please book your place now by emailing Kavi Burke, Operations Manager: Kavi@axisconsulting.ie.

Category:
View basket

Description

  • Tuesday, January 25th, 2021
  • Virtual Event
  • 11:00am – 12:15pm GMT
CONTACT US